Technology Overview

TALi is an Australian digital health company delivering diagnostic and therapeutic solutions to improve cognitive function and behaviour. Based on a foundation of over 25 years research, TALi’s first suite of clinically-validated solutions leverage a gamified platform to assess and improve cognitive performance associated with attention deficits during early childhood, a critical age of development. TALi has leveraged research from one of Australia’s leading neuroscience institutes with its software development and game design team combining to deliver world-leading digital health programs.

The TALi program is based on the concept of “neuroplasticity” – a term used to mean that the brain is plastic (or flexible), and can be re-wired by both experience and training. Recent scientific findings indicate that intense training in childhood can result in changes at many levels in the brain, which in turn promote changes in cognitive skills and behaviour.

The company’s vision is to be one of the global leaders in continuing to develop scalable digital therapeutic technologies to address debilitating congenital and acquired cognitive impairments. Commercial, clinical and development partners are sought to accelerate the delivery of this ground-breaking digital solutions to Singapore and the greater ASEAN region.

Technology Features, Specifications and Advantages

TALi has built gamified app technology, the first iteration of which targets cognitive attention skills during early childhood through its breakthrough evidence a video-gamed-based TALi screening (‘DETECT’) and training (‘TRAIN’). The apps are available on the Google Play store for Android devices, or on the App Store for Apple devices.

TALi’s attention training program—TALi TRAIN—has been assessed in a rigorous, double-blind, randomised control trial, considered the ‘gold standard’ method of assessing interventions. After five weeks of using TALi TRAIN, children showed greater improvements in their ability to select relevant information and filter out distractors (Selective Attention), compared to children who used a control program for the same length of time. These attentional improvements were still present three months after the children had stopped using the program. Additionally, TALi TRAIN was shown to promote benefits in untrained academic skills, such as numeracy, at the three-month follow-up assessment.

TALi is an Official Google for Education Partner, is NDIS registered (which means that Australians who are part of the National Disability Insurance Scheme can claim the cost of TALi programs) and TALi TRAIN is classified as a medical device (ARTG Class 1, FDA Class 2 and CE Mark).

Potential Applications

Innovations that target cognitive skills to deliver non-invasive early interventions underpin the TALi platform technology that is allowing the Company to deliver a series of product developments in the following disorders for predictive diagnosis and treatment:

• ADHD (Attention Deficit Hyperactivity Disorder)
• ASD (Autism Spectrum Disorder)

Along with a core research program exploring applications for at populations afflicted with Mild Cognitive Impairment (MCI has been found to often been a precursor to recognizing Alzheimer’s disease and other forms of dementia). TALi solutions are delivering advances in human cognitive function and behaviour only dreamt of a few short years ago.

Globally, 136 million children are identified as having severe attention difficulties.

Customer Benefit

Along with the apps, TALi program administration is supported by an online portal system, which allows healthcare providers to securely store their client’s information, progress and program results, as well as send administrative documents and information to parents of their clients. Assessment, compliance and progression data sets are accessible via the TALi Portal by administrators of the program.

It is clinically proven and well-known amongst the clinical community that early intervention provides the best outcomes for patients with attention difficulties. However, many clinicians are searching for non-drug based therapies to use in the early stages that provide long-term results.

The benefits of non-invasive medical technology that can be administered in a home environment are clear – bridging the gap for assessment and treatment where physical access to healthcare providers and solutions are not an option.